Ersin Erfa, general manager of Centurion, which recently set up one of Turkey’s largest biotechnology plants in Ankara, dives into the world of double-digit growth and a booming export business, while truly establishing themselves as one of Turkey’s leading biotechnology-focused companies, in addition to their historical expertise in plasma products.   What have been the key achievements and milestones of the company since we last met three years ago? Over the past eight years, Centurion has been growing at a double-digit CAGR, growing 60 percent in 2017 alone as a consequence of new legislations and the start of our new production facility. Furthermore, we have recently entered the vaccination business which is also growing fast, paving the way for our double-digit growth expectations to continue until 2023. As mentioned, production has already started in our new facility, which is one of the biggest biological production sites in Turkey, located in Ankara. Its construction was completed towards the end of 2017 and is now Good Manufacturing Practice (GMP) approved. Furthermore, it was also the first facility to be inspected by the Turkish Medicines and Medical Devices Agency (TiTCK) after it joined the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in December 2017, a great achievement which we are extremely proud of.

Production has already started in our new facility, which is one of the biggest biological production sites in Turkey, located in Ankara.